- Home
- ACRV
as 10-24-2025 3:56pm EST
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 47.8M | IPO Year: | 2022 |
| Target Price: | $17.75 | AVG Volume (30 days): | 464.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $8.74 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 805.34% |
Latest Acrivon Therapeutics Inc. News
ACRV Breaking Stock News: Dive into ACRV Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
Simply Wall St.
24 days ago
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap
GlobeNewswire
25 days ago
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
5 months ago
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
MT Newswires
5 months ago
Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating
GlobeNewswire
5 months ago
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Zacks
6 months ago
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
GlobeNewswire
6 months ago
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
Compare ACRV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRV Acrivon Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.